Apr 18, 2023 / 02:15PM GMT
Michael Stephen Matson - Needham & Company, LLC, Research Division - Senior Analyst
Good morning. Thanks for joining us at the 22nd Annual Needham Healthcare Conference. I'm Mike Matson, and I lead the med tech and diagnostics equity research team at Needham & Company. With me, we have Zimmer Biomet CEO, Ivan Tornos, Executive Vice President and CFO, Suky Upadhyay, Senior Vice President, Investor Relations and Chief Communications Officer, Kerri Mattox. Instead of a standard presentation, we're going to do a Q&A fireside chat format. If you do have questions that you would like to ask, you could submit them electronically through the Needham conference website or you can feel free to e-mail them to me at [email protected], and I'll do my best to fit them in.
Questions and Answers:
Michael Stephen Matson - Needham & Company, LLC, Research Division - Senior AnalystSo with that, we're going to go straight into the questions. I want to start out with one on the orthopedics market. The recon market, i.e., hips and knees was really strong
Trustpilot
